No lobbying activity in 2020. Client was terminated effective December 31, 2019.
Duration: February 8, 2009
to
April 1, 2020
General Issues: Budget/Appropriations , Homeland Security , Disaster Planning/Emergencies , Health Issues , Pharmacy
Spending: about $1,050,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate, House of Representatives,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2020
DAVIS & HARMAN LLP terminated an engagement in which they represented Emergent BioSolutions, Inc. on Nov. 18, 2020.
Original Filing: 301227016.xml
Lobbying Issues
No lobbying activity in 2020. Client was terminated effective December 31, 2019.
2nd Quarter, 2020
DAVIS & HARMAN LLP amended a lobbying report for representation of Emergent BioSolutions, Inc. in Q22020 on Aug. 26, 2020.
Original Filing: 301205729.xml
Lobbying Issues
No lobbying activity in 2020. Client was terminated effective December 31, 2019.
2nd Quarter, 2020
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. . The report was filed on July 17, 2020.
Original Filing: 301192303.xml
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. NDAA - provisions related to biological and chemical defense. Opioid and heroin addiction legislation. Naloxone access, coprescribing/opioid prescribing guidelines. H.R. 6800, HEROES Act. State Opioid Response Grants funding for FY 2021. Emergency Support for Substance Use Disorders Act. Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorders.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. NDAA - provisions related to biological and chemical defense. Opioid and heroin addiction legislation. Naloxone access, coprescribing/opioid prescribing guidelines. H.R. 6800, HEROES Act. State Opioid Response Grants funding for FY 2021. Emergency Support for Substance Use Disorders Act. Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorders.
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2020
DAVIS & HARMAN LLP amended a lobbying report for representation of Emergent BioSolutions, Inc. in Q12020 on Sept. 4, 2020.
Original Filing: 301206181.xml
Lobbying Issues
No lobbying activity in 2020. Client was terminated effective December 31, 2019.
1st Quarter, 2020
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. . The report was filed on April 16, 2020.
Original Filing: 301168332.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2019
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. . The report was filed on Jan. 14, 2020.
Original Filing: 301105420.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2019
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $10,000. The report was filed on Oct. 10, 2019.
Original Filing: 301064386.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines. H.R. 3877, Bipartisan Budget Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2019
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $10,000. The report was filed on July 19, 2019.
Original Filing: 301051574.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2019
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $10,000. The report was filed on April 17, 2019.
Original Filing: 301026951.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2018
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $10,000. The report was filed on Jan. 17, 2019.
Original Filing: 301006049.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical Countermeasures. H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines.
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical Countermeasures. H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines.
Type of Issue
Budget/Appropriations Disaster Planning/Emergencies
3rd Quarter, 2018
DAVIS & HARMAN LLP amended a lobbying report for representation of Emergent BioSolutions, Inc. in Q32018 on Oct. 19, 2018.
Original Filing: 300990036.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Type of Issue
Budget/Appropriations Disaster Planning/Emergencies
3rd Quarter, 2018
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Oct. 17, 2018.
Original Filing: 300986659.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Type of Issue
Budget/Appropriations Disaster Planning/Emergencies
2nd Quarter, 2018
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on July 18, 2018.
Original Filing: 300968210.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Type of Issue
Budget/Appropriations Disaster Planning/Emergencies
1st Quarter, 2018
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on April 19, 2018.
Original Filing: 300948649.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Type of Issue
Budget/Appropriations Disaster Planning/Emergencies
4th Quarter, 2017
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Jan. 19, 2018.
Original Filing: 300928500.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations Disaster Planning/Emergencies
3rd Quarter, 2017
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Oct. 19, 2017.
Original Filing: 300907998.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations Disaster Planning/Emergencies
2nd Quarter, 2017
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on July 20, 2017.
Original Filing: 300893549.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition and stockpiling medical countermeasures. Provisions related to development, acquisition and stockpiling medical countermeasures.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations Disaster Planning/Emergencies
1st Quarter, 2017
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on April 19, 2017.
Original Filing: 300870243.xml
Lobbying Issues
FY 2017 and FY 2018 Appropriations - provisions related to development, acquisition and stockpiling of medical countermeasures. Provisions related to development, acquisition and stockpiling of medical countermeasures for the US Government.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations Disaster Planning/Emergencies
4th Quarter, 2016
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Jan. 17, 2017.
Original Filing: 300846998.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security Budget/Appropriations
3rd Quarter, 2016
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828796.xml
Lobbying Issues
H.R. 5634/S. 3001,Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5634/S. 3001,Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5634/S. 3001, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2016
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 18, 2016.
Original Filing: 300811366.xml
Lobbying Issues
H.R. 5634/S. 3001,Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5634/S. 3001,Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5634/S. 3001, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Draft Department of Labor HHS Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2016
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on April 18, 2016.
Original Filing: 300793715.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
4th Quarter, 2015
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 19, 2016.
Original Filing: 300775316.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 2029, Consolidated Appropriations Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Budget/Appropriations
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act. H.R. 2029, Consolidated Appropriations Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2015
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 19, 2015.
Original Filing: 300758705.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Budget/Appropriations
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300 / S.1915, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2015
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300745554.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Budget/Appropriations
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2015
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300720087.xml
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Budget/Appropriations
Lobbying Issues
Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 1300, First Responders Anthrax Preparedness Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2014
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700059.xml
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 83, Consolidated and Further Continuing Appropriations Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.R. 83, Consolidated and Further Continuing Appropriations Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
3rd Quarter, 2014
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678268.xml
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res. 124, continuing appropriations legislation.
Agencies Lobbied
U.S. House of Representatives,
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res. 124, continuing appropriations legislation.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Homeland Security Budget/Appropriations
2nd Quarter, 2014
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 18, 2014.
Original Filing: 300660888.xml
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 4903/S. 2534, Department of Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
1st Quarter, 2014
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on April 21, 2014.
Original Filing: 300646497.xml
Lobbying Issues
Department Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department Homeland Security Appropriations -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
4th Quarter, 2013
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 20, 2014.
Original Filing: 300621506.xml
Lobbying Issues
Department Homeland Security Appropriations Act, 2014 -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res 59 -- Continuing Appropriations Resolution -- provisions related to development, acquisition and stockpiling of
biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department Homeland Security Appropriations Act, 2014 -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res 59 -- Continuing Appropriations Resolution -- provisions related to development, acquisition and stockpiling ofbiodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
3rd Quarter, 2013
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 17, 2013.
Original Filing: 300595974.xml
Lobbying Issues
Department Homeland Security Appropriations Act, 2014 -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res 59 -- Continuing Appropriations Resolution -- provisions related to development, acquisition and stockpiling of
biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department Homeland Security Appropriations Act, 2014 -- provisions related to development, acquisition and stockpiling of biodefense vaccines. Department of Labor HHS -- provisions related to development, acquisition and stockpiling of biodefense vaccines. H.J. Res 59 -- Continuing Appropriations Resolution -- provisions related to development, acquisition and stockpiling ofbiodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Budget/Appropriations
2nd Quarter, 2013
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 16, 2013.
Original Filing: 300573271.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2013
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on April 18, 2013.
Original Filing: 300553321.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2012
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 18, 2013.
Original Filing: 300534705.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2012
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 22, 2012.
Original Filing: 300518512.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2012
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 17, 2012.
Original Filing: 300487003.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2012
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on April 19, 2012.
Original Filing: 300467540.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2011
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 12, 2012.
Original Filing: 300436594.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Disaster Planning/Emergencies
3rd Quarter, 2011
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Oct. 12, 2011.
Original Filing: 300412900.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Disaster Planning/Emergencies
2nd Quarter, 2011
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 18, 2011.
Original Filing: 300393863.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.& Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Homeland Security Disaster Planning/Emergencies
1st Quarter, 2011
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on April 20, 2011.
Original Filing: 300377672.xml
Lobbying Issues
Department of Labor, Health & Human Services and Education Appropriations Act for 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. WMD Prevention and Preparedness Act - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Homeland Security Disaster Planning/Emergencies
4th Quarter, 2010
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on Jan. 19, 2011.
Original Filing: 300345807.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
3rd Quarter, 2010
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Oct. 19, 2010.
Original Filing: 300319620.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2010
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on July 19, 2010.
Original Filing: 300291894.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
1st Quarter, 2010
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on April 20, 2010.
Original Filing: 300273358.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
4th Quarter, 2009
In Q4, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $10,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246665.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on Oct. 20, 2009.
Original Filing: 300217446.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
2nd Quarter, 2009
In Q2, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $30,000. The report was filed on July 20, 2009.
Original Filing: 300189888.xml
Lobbying Issues
Issues related to the Antthrax vaccine and other bipharmaceutical products.
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
1st Quarter, 2009
In Q1, DAVIS & HARMAN LLP lobbied for Emergent BioSolutions, Inc. , earning $20,000. The report was filed on April 20, 2009.
Original Filing: 300161954.xml
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
DAVIS & HARMAN LLP amended a lobbying report for representation of Emergent BioSolutions, Inc. in Q12009 on April 20, 2009.
Original Filing: 300162039.xml
Lobbying Issues
Issues related to the Anthrax vaccine and other biopharmaceutical products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Health Issues
Lobbying Issues
Issues related to Anthrax vaccine and other biopharmaceuticals products.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
Davis & Harman LLP filed a lobbying registration on April 8, 2009 to represent Emergent BioSolutions, Inc., effective Feb. 8, 2009.
Original Filing: 300145550.xml
Issue(s) they said they’d lobby about: Issues related to the Anthrax vaccine and other biopharmaceutical products .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate